FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195419801> ?p ?o ?g. }

• W3195419801 endingPage "1321" @default.
• W3195419801 startingPage "1312" @default.
• W3195419801 abstract "Background Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma. Methods This multicentre, open-label, multicohort, phase 1/2 trial was done at 17 hospitals in six countries. Eligible patients were aged 2–25 years, had relapsed or refractory osteosarcoma, measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1, Lansky play–performance score or Karnofsky performance score of 50% or higher, up to one previous VEGF or VEGF receptor-targeted therapy, and a life expectancy of at least 3 months. This study includes a combination dose-finding phase 1 part (cohort 3A) and a phase 2 combination expansion in patients with osteosarcoma (cohort 3B). Lenvatinib was administered orally at a starting dose of 11 mg/m2 per day, capped at 24 mg per day, and etoposide (100 mg/m2 per day) plus ifosfamide (3000 mg/m2 per day) were administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. Lenvatinib monotherapy continued after these five cycles until disease progression, toxic effects, or patient choice to discontinue. The phase 1 primary endpoint was to determine the recommended phase 2 dose by evaluating dose-limiting toxicity and the phase 2 primary endpoint was progression-free survival at 4 months. Progression-free survival was measured in the full analysis set, which included all patients enrolled for efficacy outcomes; safety was assessed in all patients who received any study drug. This study is registered with ClinicalTrials.gov, NCT02432274. Findings 30 patients were screened for enrolment into cohort 3A between May 9, 2016, and June 3, 2019, and 22 patients for enrolment into cohort 3B between Sept 13, 2018, and July 18, 2019. Eight patients from cohort 3A and two from cohort 3B were ineligible for enrolment in the study. In phase 1, dose-limiting toxicities were observed in three patients (one in the lenvatinib 11 mg/m2 combination group and two in the 14 mg/m2 combination group) and the recommended phase 2 dose was determined as lenvatinib 14 mg/m2 per day (with daily dose cap of 24 mg) and etoposide 100 mg/m2 per day plus ifosfamide 3000 mg/m2 per day administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. 35 patients from phase 1 (cohort 3A; n=15) and phase 2 (cohort 3B; n=20) were treated at the recommended phase 2 dose and their results were pooled. Progression-free survival at 4 months was 51% (95% CI 34–69) in 18 of 35 patients per the binomial estimate. The most common grade 3–4 treatment-emergent adverse events were neutropenia (27 [77%] of 35), thrombocytopenia (25 [71%]), anaemia (19 [54%]), and decreased white blood cell count (19 [54%]). 26 [74%] of 35 patients had serious treatment-emergent adverse events and no treatment-related deaths occurred. Interpretation Lenvatinib with etoposide plus ifosfamide shows promising antitumour activity with no new safety signals in patients with refractory and relapsed osteosarcoma. These findings warrant further investigation in an ongoing randomised phase 2 study (NCT04154189). Funding Eisai and Merck Sharp & Dohme. Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma. This multicentre, open-label, multicohort, phase 1/2 trial was done at 17 hospitals in six countries. Eligible patients were aged 2–25 years, had relapsed or refractory osteosarcoma, measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1, Lansky play–performance score or Karnofsky performance score of 50% or higher, up to one previous VEGF or VEGF receptor-targeted therapy, and a life expectancy of at least 3 months. This study includes a combination dose-finding phase 1 part (cohort 3A) and a phase 2 combination expansion in patients with osteosarcoma (cohort 3B). Lenvatinib was administered orally at a starting dose of 11 mg/m2 per day, capped at 24 mg per day, and etoposide (100 mg/m2 per day) plus ifosfamide (3000 mg/m2 per day) were administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. Lenvatinib monotherapy continued after these five cycles until disease progression, toxic effects, or patient choice to discontinue. The phase 1 primary endpoint was to determine the recommended phase 2 dose by evaluating dose-limiting toxicity and the phase 2 primary endpoint was progression-free survival at 4 months. Progression-free survival was measured in the full analysis set, which included all patients enrolled for efficacy outcomes; safety was assessed in all patients who received any study drug. This study is registered with ClinicalTrials.gov, NCT02432274. 30 patients were screened for enrolment into cohort 3A between May 9, 2016, and June 3, 2019, and 22 patients for enrolment into cohort 3B between Sept 13, 2018, and July 18, 2019. Eight patients from cohort 3A and two from cohort 3B were ineligible for enrolment in the study. In phase 1, dose-limiting toxicities were observed in three patients (one in the lenvatinib 11 mg/m2 combination group and two in the 14 mg/m2 combination group) and the recommended phase 2 dose was determined as lenvatinib 14 mg/m2 per day (with daily dose cap of 24 mg) and etoposide 100 mg/m2 per day plus ifosfamide 3000 mg/m2 per day administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. 35 patients from phase 1 (cohort 3A; n=15) and phase 2 (cohort 3B; n=20) were treated at the recommended phase 2 dose and their results were pooled. Progression-free survival at 4 months was 51% (95% CI 34–69) in 18 of 35 patients per the binomial estimate. The most common grade 3–4 treatment-emergent adverse events were neutropenia (27 [77%] of 35), thrombocytopenia (25 [71%]), anaemia (19 [54%]), and decreased white blood cell count (19 [54%]). 26 [74%] of 35 patients had serious treatment-emergent adverse events and no treatment-related deaths occurred. Lenvatinib with etoposide plus ifosfamide shows promising antitumour activity with no new safety signals in patients with refractory and relapsed osteosarcoma. These findings warrant further investigation in an ongoing randomised phase 2 study (NCT04154189)." @default.
• W3195419801 created "2021-08-30" @default.
• W3195419801 creator A5000472375 @default.
• W3195419801 creator A5002275757 @default.
• W3195419801 creator A5006570922 @default.
• W3195419801 creator A5007096008 @default.
• W3195419801 creator A5007564466 @default.
• W3195419801 creator A5011342082 @default.
• W3195419801 creator A5014514185 @default.
• W3195419801 creator A5015760028 @default.
• W3195419801 creator A5019781329 @default.
• W3195419801 creator A5022712318 @default.
• W3195419801 creator A5038316850 @default.
• W3195419801 creator A5042760390 @default.
• W3195419801 creator A5047205597 @default.
• W3195419801 creator A5051760830 @default.
• W3195419801 creator A5052857128 @default.
• W3195419801 creator A5054237397 @default.
• W3195419801 creator A5058747709 @default.
• W3195419801 creator A5060861215 @default.
• W3195419801 creator A5062715691 @default.
• W3195419801 creator A5066172709 @default.
• W3195419801 creator A5083818934 @default.
• W3195419801 creator A5085457887 @default.
• W3195419801 date "2021-09-01" @default.
• W3195419801 modified "2023-10-13" @default.
• W3195419801 title "Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study" @default.
• W3195419801 cites W1540759505 @default.
• W3195419801 cites W1975253840 @default.
• W3195419801 cites W1976262446 @default.
• W3195419801 cites W2061034742 @default.
• W3195419801 cites W2115852392 @default.
• W3195419801 cites W2155903913 @default.
• W3195419801 cites W2167348613 @default.
• W3195419801 cites W2195486425 @default.
• W3195419801 cites W2473766695 @default.
• W3195419801 cites W2591072493 @default.
• W3195419801 cites W2666404417 @default.
• W3195419801 cites W2755804993 @default.
• W3195419801 cites W2758151211 @default.
• W3195419801 cites W2889673034 @default.
• W3195419801 cites W2894974756 @default.
• W3195419801 cites W2904481169 @default.
• W3195419801 cites W2941090871 @default.
• W3195419801 cites W3006622491 @default.
• W3195419801 cites W4243636416 @default.
• W3195419801 doi "https://doi.org/10.1016/s1470-2045(21)00387-9" @default.
• W3195419801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34416158" @default.
• W3195419801 hasPublicationYear "2021" @default.
• W3195419801 type Work @default.
• W3195419801 sameAs 3195419801 @default.
• W3195419801 citedByCount "45" @default.
• W3195419801 countsByYear W31954198012021 @default.
• W3195419801 countsByYear W31954198012022 @default.
• W3195419801 countsByYear W31954198012023 @default.
• W3195419801 crossrefType "journal-article" @default.
• W3195419801 hasAuthorship W3195419801A5000472375 @default.
• W3195419801 hasAuthorship W3195419801A5002275757 @default.
• W3195419801 hasAuthorship W3195419801A5006570922 @default.
• W3195419801 hasAuthorship W3195419801A5007096008 @default.
• W3195419801 hasAuthorship W3195419801A5007564466 @default.
• W3195419801 hasAuthorship W3195419801A5011342082 @default.
• W3195419801 hasAuthorship W3195419801A5014514185 @default.
• W3195419801 hasAuthorship W3195419801A5015760028 @default.
• W3195419801 hasAuthorship W3195419801A5019781329 @default.
• W3195419801 hasAuthorship W3195419801A5022712318 @default.
• W3195419801 hasAuthorship W3195419801A5038316850 @default.
• W3195419801 hasAuthorship W3195419801A5042760390 @default.
• W3195419801 hasAuthorship W3195419801A5047205597 @default.
• W3195419801 hasAuthorship W3195419801A5051760830 @default.
• W3195419801 hasAuthorship W3195419801A5052857128 @default.
• W3195419801 hasAuthorship W3195419801A5054237397 @default.
• W3195419801 hasAuthorship W3195419801A5058747709 @default.
• W3195419801 hasAuthorship W3195419801A5060861215 @default.
• W3195419801 hasAuthorship W3195419801A5062715691 @default.
• W3195419801 hasAuthorship W3195419801A5066172709 @default.
• W3195419801 hasAuthorship W3195419801A5083818934 @default.
• W3195419801 hasAuthorship W3195419801A5085457887 @default.
• W3195419801 hasBestOaLocation W31954198011 @default.
• W3195419801 hasConcept C121608353 @default.
• W3195419801 hasConcept C126322002 @default.
• W3195419801 hasConcept C142424586 @default.
• W3195419801 hasConcept C143998085 @default.
• W3195419801 hasConcept C191897082 @default.
• W3195419801 hasConcept C192562407 @default.
• W3195419801 hasConcept C2776264508 @default.
• W3195419801 hasConcept C2776694085 @default.
• W3195419801 hasConcept C2777506904 @default.
• W3195419801 hasConcept C2778119113 @default.
• W3195419801 hasConcept C2779761222 @default.
• W3195419801 hasConcept C3019800554 @default.
• W3195419801 hasConcept C31760486 @default.
• W3195419801 hasConcept C535046627 @default.
• W3195419801 hasConcept C71924100 @default.
• W3195419801 hasConceptScore W3195419801C121608353 @default.
• W3195419801 hasConceptScore W3195419801C126322002 @default.
• W3195419801 hasConceptScore W3195419801C142424586 @default.
• W3195419801 hasConceptScore W3195419801C143998085 @default.

• next